

#9 attachment  
09/7/232

Docket No. PF-0525 USN  
USSN: 09701,232  
Ref. No. 1

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |  |  |
|--|--|--|--|
| (51) International Patent Classification <sup>6</sup> :<br>C12N 15/12, C07K 14/47, C12N 15/63,<br>C07K 16/18, G01N 33/68, C12Q 1/68  |  | A1   | (11) International Publication Number: <b>WO 99/49032</b><br>(43) International Publication Date: 30 September 1999 (30.09.99) |
| (21) International Application Number: PCT/EP98/07806<br>(22) International Filing Date: 2 December 1998 (02.12.98)  |  | (81) Designated States: JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  |  |
| (30) Priority Data:<br>9806222.7 23 March 1998 (23.03.98) GB<br>9820299.7 17 September 1998 (17.09.98) GB  |  | Published<br>With international search report.<br>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. |  |
| (71) Applicant: SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).   |  |  |  |
| (72) Inventors: MICHALOVICH, David; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). SIMS, Matthew, A.; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). SHAIKH, Narjis; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). |  |  |  |
| (74) Agent: CONNELL, Anthony, Christopher; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).   |  |  |  |
| (54) Title: SUPPRESSORS OF CYTOKINE SIGNALLING   |  |  |  |
| (57) Abstract<br>SBHWSB1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SBHWSB1 polypeptides and polynucleotides in therapy, and diagnostic assays for such.   |  |  |  |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |   |    |                          |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania                  | ES | Spain                                 | LS | Lesotho                                   | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                               | LT | Lithuania                                 | SK | Slovakia                 |
| AT | Austria                  | FR | France                                | LU | Luxembourg                                | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                 | LV | Latvia                                    | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                        | MC | Monaco                                    | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                               | MD | Republic of Moldova                       | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                 | MG | Madagascar                                | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                | ML | Mali                                      | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                               | MN | Mongolia                                  | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                               | MR | Mauritania                                | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                | MW | Malawi                                    | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                               | MX | Mexico                                    | US | United States of America |
| CA | Canada                   | IT | Italy                                 | NE | Niger                                     | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                 | NL | Netherlands                               | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                 | NO | Norway                                    | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                            | NZ | New Zealand                               | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's Republic of Korea | PL | Poland                                    |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                     | PT | Portugal                                  |    |                          |
| CN | China                    | KZ | Kazakhstan                            | RO | Romania                                   |    |                          |
| CU | Cuba                     | LC | Saint Lucia                           | RU | Russian Federation                        |    |                          |
| CZ | Czech Republic           | LJ | Liechtenstein                         | SD | Sudan                                     |    |                          |
| DE | Germany                  | LK | Sri Lanka                             | SE | Sweden                                    |    |                          |
| DK | Denmark                  | LR | Liberia                               | SG | Singapore                                 |    |                          |
| EE | Estonia                  |    |                                       |    |   |    |                          |

## SUPPRESSORS OF CYTOKINE SIGNALLING

**Field of the Invention**

This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

**Background of the Invention**

The drug discovery process is currently undergoing a fundamental revolution as it embraces 'functional genomics', that is, high throughput genome- or gene-based biology. This approach means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on 'positional cloning'. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

**Summary of the Invention**

The present invention relates to SBHWSB1, in particular SBHWSB1 polypeptides and SBHWSB1 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of cancer, obesity, inflammatory disorders, heart disease, Crohn's diseases, neuropathies and immune disorders, hereinafter referred to as "the Diseases", amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with SBHWSB1 imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate SBHWSB1 activity or levels.

**30 Description of the Invention**

In a first aspect, the present invention relates to SBHWSB1 polypeptides. Such peptides include isolated polypeptides comprising an amino acid sequence which has at least 95% identity,

preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the amino acid of SEQ ID NO:2.

- Further peptides of the present invention include isolated polypeptides in which the amino acid sequence has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2.

Further peptides of the present invention include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:1.

- Polypeptides of the present invention are believed to be members of the WD40 SOCS box family of polypeptides. They are therefore of interest because SOCS box containing proteins are implicated in acting as a negative regulators of cytokine signalling by interacting with and hence inhibiting the function of the Janus kinase (JAK) family of protein kinases. This in turn is thought to prevent further signal transduction through the cytokine JAK/STAT pathway (D.J. Hilton et al., PNAS 95:114-119, 1998). These properties are hereinafter referred to as SBHWSB1 activity" or SBHWSB1 polypeptide activity" or "biological activity of SBHWSB1". Also included amongst these activities are antigenic and immunogenic activities of said SBHWSB1 polypeptides, in particular the antigenic and immunogenic activities of the polypeptide of SEQ ID NO:2. Preferably, a polypeptide of the present invention exhibits at least one biological activity of SBHWSB1.

- The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, prosequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

- The present invention also includes variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced

polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to SBHWSB1 polynucleotides. Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 95% identity to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:1 encoding the polypeptide of SEQ ID NO:2.

Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 95% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.

Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence which has at least 95% identity to SEQ ID NO:1 over the entire length of SEQ ID NO:1. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 as well as the polynucleotide of SEQ ID NO:1.

The invention also provides polynucleotides which are complementary to all the above described polynucleotides.

The nucleotide sequence of SEQ ID NO:1 shows homology with mouse WSB-1 (D.J. Hilton et al., PNAS 95:114-119, 1998). The nucleotide sequence of SEQ ID NO:1 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 139 to 1305) encoding a polypeptide of 389 amino acids, the polypeptide of SEQ ID NO:2. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:1 or it may be a sequence other than the one contained in SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The polypeptide of the SEQ ID NO:2 is structurally related to other proteins of the WD40 SOCS box family, having homology and/or structural similarity with mouse WSB-1 (D.J. Hilton et al., PNAS 95:114-119, 1998).

Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one SBHWSB1 activity.

- 5       The present invention also relates to partial or other polynucleotide and polypeptide sequences which were first identified prior to the determination of the corresponding full length sequences of SEQ ID NO:1 and SEQ ID NO:2.

Accordingly, in a further aspect, the present invention provides for an isolated polynucleotide which:

- 10       (a) comprises a nucleotide sequence which has at least 95% identity, preferably at least 97-99% identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3;
- (b) has a nucleotide sequence which has at least 95% identity, preferably at least 97-99% identity, to SEQ ID NO:3 over the entire length of SEQ ID NO:3;
- (c) is the polynucleotide of SEQ ID NO:3; or
- 15       (d) a nucleotide sequence encoding a polypeptide which has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4, over the entire length of SEQ ID NO:4.

The present invention further provides for a polypeptide which:

- (a) comprises an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4;
- 20       (b) has an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4;
- (c) comprises the amino acid of SEQ ID NO:4; and
- (d) is the polypeptide of SEQ ID NO:4;
- 25       as well as polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

- The nucleotide sequence of SEQ ID NO:3 and the peptide sequence encoded thereby are derived from EST (Expressed Sequence Tag) sequences. It is recognised by those skilled in the art that there will inevitably be some nucleotide sequence reading errors in EST sequences (see
- 30       Adams, M.D. *et al.* Nature 377 (supp) 3, 1995). Accordingly, the nucleotide sequence of SEQ ID NO:3 and the peptide sequence encoded therefrom are therefore subject to the same inherent limitations in sequence accuracy. Furthermore, the peptide sequence encoded by SEQ ID NO:3 comprises a region of identity or close homology and/or close structural similarity (for example a conservative amino acid difference) with the closest homologous or structurally similar protein.

Polynucleotides of the present invention may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human placenta, melanocyte, lung, fetal heart, heart, T-cell, parathyroid, retina and brain using the expressed sequence tag (EST) analysis (Adams, M.D., *et al.* Science (1991) 252:1651-1656; Adams, M.D. 5 *et al.*, Nature, (1992) 355:632-634; Adams, M.D., *et al.*, Nature (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for 10 the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred 15 embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Further embodiments of the present invention include polynucleotides encoding polypeptide 20 variants which comprise the amino acid sequence of SEQ ID NO:2 and in which several, for instance from 5 to 10, 1 to 5, 1 to 3, 1 to 2 or 1, amino acid residues are substituted, deleted or added, in any combination.

Polynucleotides which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO:1, may be used as hybridization probes for cDNA and genomic DNA or as 25 primers for a nucleic acid amplification (PCR) reaction, to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to SEQ ID NO:1. Typically these nucleotide sequences are 70% identical, preferably 80% identical, more preferably 90% 30 identical, most preferably 95% identical to that of the referent. The probes or primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes polynucleotides obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide is short at the 5' end of the cDNA. This is a consequence of reverse transcriptase, an enzyme with inherently low 'processivity' (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during 1st strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., PNAS USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the 'missing' 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analysed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.



Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems which comprise a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector which is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., Molecular Cloning, A Laboratory Manual (supra). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum,

the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and or purification.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled SBHWSB1 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, e.g., Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotides probes

- comprising SBHWSB1 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee et al., Science, Vol 274, pp 610-613 (1996)).

- The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the SBHWSB1 gene by the methods described. In addition, such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of polypeptide or mRNA.
- Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

- Thus in another aspect, the present invention relates to a diagnostic kit which comprises:
- (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment thereof;
  - (b) a nucleotide sequence complementary to that of (a);
  - (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 or a fragment thereof; or
  - (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2.
- It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly cancer, obesity, inflammatory disorders, heart disease, Crohn's diseases, neuropathies and immune disorders, amongst others.

- The nucleotide sequences of the present invention are also valuable for chromosomal localisation. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such

data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

- 5       The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

- 10       The nucleotide sequences of the present invention are also valuable for tissue localisation. Such techniques allow the determination of expression patterns of the human SBHWSB1 polypeptides in tissues by detection of the mRNAs that encode them. These techniques include in situ hybridization techniques and nucleotide amplification techniques, for example PCR. Such techniques are well known in the art. Results from these studies provide an indication of the normal functions of the polypeptides in the organism. In addition, comparative  
15       studies of the normal expression pattern of human SBHWSB1 mRNAs with that of mRNAs encoded by a human SBHWSB1 gene provide valuable insights into the role of mutant human SBHWSB1 polypeptides, or that of inappropriate expression of normal human SBHWSB1 polypeptides, in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

- 20       The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

- 25       Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-  
30       497), the trioma technique, the human B-cell hybridoma technique (Kozboret *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this

invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

- 5 Antibodies against polypeptides of the present invention may also be employed to treat the Diseases, amongst others.

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various  
10 subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use  
15 thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with a polypeptide of the  
20 present invention, adequate to produce antibody and/or T cell immune response to protect said animal from the Diseases hereinbefore mentioned, amongst others. Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering a polypeptide of the present invention via a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological  
25 response to produce antibody to protect said animal from diseases.

A further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a polypeptide of the present invention wherein the composition comprises a polypeptide or polynucleotide of the present invention. The vaccine formulation may  
30 further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous

and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include  
5    adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention are responsible for one or more biological functions, including one or more disease states, in particular the Diseases hereinbefore mentioned. It is  
10    therefore desirous to devise screening methods to identify compounds which stimulate or which inhibit the function of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate or which inhibit the function of the polypeptide. In general, agonists or antagonists may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned. Compounds may be  
15    identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists, antagonists or inhibitors so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; or may be structural or functional mimetics thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)).

20    The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or  
25    inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Constitutively active polypeptides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate  
30    compound results in inhibition of activation of the polypeptide. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring SBHWSB1 activity in the mixture, and comparing the SBHWSB1 activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and SBHWSB1 polypeptide, as hereinbefore described, can

also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

- 5 The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called
- 10 antagonist or agonist, respectively) from suitably manipulated cells or tissues.

- The polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance,  $^{125}\text{I}$ ), chemically modified (for instance, biotinylated), or fused to a peptide
- 15 sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide which compete with the binding of the polypeptide to its receptors, if any. Standard methods for
- 20 conducting such assays are well understood in the art.

- Examples of potential polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or small molecules which bind to the polypeptide of the present invention but do not
- 25 elicit a response, so that the activity of the polypeptide is prevented.

Thus, in another aspect, the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which decrease or enhance the production of such polypeptides, which comprises:

- 30 (a) a polypeptide of the present invention;  
(b) a recombinant cell expressing a polypeptide of the present invention;  
(c) a cell membrane expressing a polypeptide of the present invention; or  
(d) antibody to a polypeptide of the present invention;  
which polypeptide is preferably that of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist, antagonist or inhibitor of the polypeptide, by:

- (a) determining in the first instance the three-dimensional structure of the polypeptide;
  - (b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist, antagonist or inhibitor;
  - (c) synthesizing candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and
  - (d) testing whether the candidate compounds are indeed agonists, antagonists or inhibitors.
- It will be further appreciated that this will normally be an iterative process.

In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, cancer, obesity, inflammatory disorders, heart disease, Crohn's diseases, neuropathies and immune disorders, related to either an excess of, or an under-expression of, SBHWSB1 polypeptide activity.

If the activity of the polypeptide is in excess, several approaches are available. One approach comprises administering to a subject in need thereof an inhibitor compound (antagonist) as hereinabove described, optionally in combination with a pharmaceutically acceptable carrier, in an amount effective to inhibit the function of the polypeptide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition. In another approach, soluble forms of the polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous polypeptide may be administered. Typical examples of such competitors include fragments of the SBHWSB1 polypeptide.

In still another approach, expression of the gene encoding endogenous SBHWSB1 polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or externally administered (see, for example, O'Connor, J Neurochem (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Alternatively, oligonucleotides which form triple helices ("triplexes") with the gene can be supplied (see, for example, Lee *et al.*, Nucleic Acids Res (1979) 6:3073; Cooney *et al.*, Science (1988) 241:456; Dervan *et al.*, Science (1991) 251:1360). These oligomers can be administered *per se* or the relevant oligomers can be expressed *in vivo*. Synthetic antisense or triplex oligonucleotides may



comprise modified bases or modified backbones. Examples of the latter include methylphosphonate, phosphorothioate or peptide nucleic acid backbones. Such backbones are incorporated in the antisense or triplex oligonucleotide in order to provide protection from degradation by nucleases and are well known in the art. Antisense and triplex molecules

- 5 synthesised with these or other modified backbones also form part of the present invention.

In addition, expression of the human SBHWSB1 polypeptide may be prevented by using ribozymes specific to the human SBHWSB1 mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, et al., Curr. Opin. Struct. Biol (1996) 6(4), 527-33.) Synthetic ribozymes can be designed to specifically cleave

10 human SBHWSB1 mRNAs at selected positions thereby preventing translation of the human SBHWSB1 mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules. Alternatively the ribozymes may be synthesised with non-natural backbones to provide protection from ribonuclease degradation, for example, 2'-O-methyl RNA, and may contain modified bases.

- 15 For treating abnormal conditions related to an under-expression of SBHWSB1 and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to
- 20 effect the endogenous production of SBHWSB1 by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces
- 25 infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo*. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another approach is to administer a therapeutic amount of a
- 30 polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide, such as the soluble form of a polypeptide of the present invention, agonist/antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are

not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Polypeptides and other compounds of the present invention may be employed alone or in

- 5 conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal

10 administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like.

The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100  $\mu\text{g/kg}$  of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher

20 dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a

25 polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

Polynucleotide and polypeptide sequences form a valuable information resource with which to identify further sequences of similar homology. This is most easily facilitated by storing the sequence in a computer readable medium and then using the stored data to search a sequence

30 database using well known searching tools, such as those in GCG and Lasergene software packages. Accordingly, in a further aspect, the present invention provides for a computer readable medium having stored thereon a polynucleotide comprising the sequence of SEQ ID NO:1 and/or a polypeptide sequence encoded thereby.

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

"Polynucleotide" generally refers to any polyribonucleotide or polydeoxiribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.

"Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.

"Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone,

the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching.

- 5 Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, 10 disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for 15 instance, *Proteins - Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., *Post-translational Protein Modifications: Perspectives and Prospects*, pgs. 1-12 in *Post-translational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: 20 Post-translational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62).

- "Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a 25 polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many 30 regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that

is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

- "Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.
- 5 In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, 10 Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity 15 are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Altschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 20 (1990). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Preferred parameters for polypeptide sequence comparison include the following:

- 25 1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)  
Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, *Proc. Natl. Acad. Sci. USA.* 89:10915-10919 (1992)  
Gap Penalty: 12  
Gap Length Penalty: 4
- 30 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Preferred parameters for polynucleotide comparison include the following:

- 1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

- Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the default parameters for nucleic acid comparisons.

- By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:1 by the numerical percent of the respective percent identity (divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \cdot y),$$

- wherein  $n_n$  is the number of nucleotide alterations,  $x_n$  is the total number of nucleotides in SEQ ID NO:1, and  $y$  is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, etc., and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

- Similarly, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the

numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \cdot y),$$

- wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:2, and  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a subject sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the sequences being compared as hereinbefore described. Falling within this generic term are the terms "ortholog", meaning a polynucleotide or polypeptide that is the functional equivalent of a polynucleotide or polypeptide in another species, and "paralog" meaning a functionally similar sequence when considered within the same species.

- "Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

- All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

## SEQUENCE INFORMATION

## SEQ ID NO:1

TTGCGCGCCGCCCCGCCGCTCTCTCTGTCCCTGGGCCCCGGGAGGGACCAACTTTGGCGTC  
 5 ACGCCCTCAGCGSGTGCACCCTCTCTCTCTGTTGTGGTCCGCATCGTATTCCCGGAA  
 TCAGACGGTGCCCATAGATGGCCAGCTTTCCCCGAGGGTCAACGAGAAAGAGATCGTG  
 AGATCAGCTACTATAGGTGAACCTTTAGCTCCTGCAGCTCCTTTTGACAAGAAATGTGGT  
 CGTGAAATTTGGACTGTGTCTTTTGCTCCAGATGGTTCATACTTTGCTTGTCACAAGGA  
 CATCGCACAGTAAAGCTTGTTCGCTGGTCCAGTGCCTTCAGAACTTTCTCTTGCAATGSC  
 ACCAAGATGTTACCAATTCAAGCAGTTTAAAGATTGCCAAGACAAAATAGTGATGGTGGT  
 10 CAGAAAAATAAGCCTCTGTGAACATATTATAGACTGTGGAGATATAGTCTGGAGCTTTGCT  
 TTTTGGTCTACAGTTCAGAAAAACAGAGTCGCTGTGTAAATATAGAATGGCATCGCTTC  
 AGATTGGACAAGATCAGCTACTTCTTGCTACAGGGTTGAACATGGGCGTATCAAAAATA  
 TGGGATGTATATACAGGAAAACTCCTCCTTAACTTGGTAGATCATACTGAAGTGGTCAGA  
 GATTTAACTTTTGCTCCAGATGGAAGCTTGATCCTGGTGTACAGCTTCAAGAGACAAAAT  
 15 CTCAGAGTATGGGACCTGAAAGATGATGGAACATGATGAAAGTATTGAGGGGATCAG  
 AATTGGGTGTACAGCTGTGCATTCTCTCCTGACTCTCTATGCTGTGTTTCAGTCGGAGCC  
 AGTAAAGCAGTTTTCCTTTGGAATATGGATAAATACCCATGATACGGAATATAGAAGGA  
 CATCACCATGATGTGGTAGCTTGTGACTTTTCTCCTGATGGAGCACTACTGGCTACTGCA  
 TCTATGATACTCGAGTATATATCTGGGATCCACATAATGGAGACATTCTGATGGAATTT  
 20 GGGCACCTGTTTCCCCCACTACTCCAATTTTGTGGAGGAGCAATGACCGGTGGGTA  
 CGATCTGTATCTTTTAGCCATGATGGAGTCATGTTGCAAGCCTTGCTGATGATAAAATG  
 GTGAGGTTCTGGAGAATTGATGAGGATTATCCAGTSCAAGTTGCACCTTTGAGCAATGGT  
 CTTTGCTGTGCCTTCTCTACTGATGGCAGTGTTTAGCTGCTGTAGGGTGGGATTTC  
 CCATGTTGCGCTGGCTGGTCTCAAACTCCTGACCCTGACCTCAAGTGATCTTCCCGCCTC  
 25 AACTTCCCAAAGTCTGGGATTACAGGCGACACATGACGGAAGTGTGATTTTGGGCCA  
 CTCACGGCAGTCCCTAGCCTGCAACATTTATGTGCGATGTCAATCCGAAGAGTATGATG  
 CCACCCAAAGAAATTGAGGAGCTGCCGATTCCTTCCAAGCTTTTGGAGTTTCTCTCGTATC  
 GTATTAGAAGATTCTGCCTTCCCTAGTAGTAGGGACTGACAGAATACACTTAAACAAAA  
 CCTCAAGCTTTTACTGACTTCAATTATCTGTTTTTAAAGACGTAGAAGATTTATTTAAATT  
 30 GATATGTTCTTGACTGCAATTTTGATCAGTTGAGCTTTTAAATATATTATATAGACAAAT  
 AGAAGATTCTTGAACATATCAATATAAAATTTTTTAAAGATCTAACTGTGAAACATA  
 CATACCTGTACATATTAGATATAAGCTGCTATATGTTGAATGGACCTTTTGTCTTTCT  
 GATTTTATGTTCTGACATGTATATTGCTTCAGTAGAGCCACAATATGTATCTTTGCTG  
 TAAAGTGCAAGGAAATTTTAAATTCGGGCACTGAGTTAGATGGTAAATACACTGACTTAC  
 35 GAAAGTTGAATTGGGTGAGGCGGCAAAATCACCTGAGGTGACAGTTTGAGACTAGCCTG  
 GCAACATGATGAAACCTGTCTCTACTAAAAATCCTCGTGCCGAATCTTGGCCTCGAG  
 GGCCAAATCCCTATAGTGAGTCGTATT

## SEQ ID NO:2

40 MASFFPRVNEKEIVRSRTIGELLAPAAPFDKKCGRENWTVAFAPDGSYFANSQGHRTVKL  
 VWSQCLQNFLLHGTKNVTNSSRLRPRQNSDGGQKNKPREHIDCGDIVNSLAFWSVP  
 EKQSRVCNIEWHRFRFGQDQLLATGLNNGRIKIWDVYTGKLLNLVDHTEVVRDLTFAP



DGSLILVSAASRDKTLRVVDLKKDDGNMMKVLRGHQNVVYSCAFSPDSSMLCSVGASKAVFL  
 WNMDKYTMIRKLEGGHHHDVACDFSPDGALLATASVYDTRVYIWDPHNGDILMEFGLFFP  
 PTPIFAGGANDRWVRVSFSFHDGLHVASLADDKMRVFRWRIDEYVPVQVAPLSNGLCCAFS  
 TDGSLAAGRVGISPCSPGWSQTPDPLK

5

## SEQ ID NO:3

CGGCGCTTTAGGGGAACGTCTTCCCTCCGACGCGAGGCTGGGTACAGGGCTATTGTG  
 TGTGGTTGACTCCGTACTTTGGTCTGAGGCTTCGGAGCTTTCCGAGGCAGTTAGCAG  
 AAGCGCAGCGCGCGCCCCCGCCCTCTCCTCTGCTCCCTGGGCGCGGAGACAACTTGG  
 10 CGTCAGCGCCCTCAGCGGTGCGCACTCTCTCTGTTGTTGGGTCCGCACTCGTATTTCCG  
 GAATCAGACGCTGCCCATAGATGGCCAGCTTTCCCCCGAGGCTCAACGAGAAAGAGATC  
 GTGAGATTACGTACTATAGGTGAACCTTTAGCTCCTGCAGCTCCTTTGACAGAAATGT  
 GGTGCGTAAAAATTGGAAGCTTTGCTTTGCTCCAGATGGTTCATACTTTGCTTGGTCACAA  
 GGACATCGCACAGTAAAGCTTGTTCGGTGGTCCAGTGCCTTCAGAACTTTCTCTGCAAT  
 15 GGCACCAAGAAATGTTACCAATTCAAGCAGTTTAAAGATTGCCAAGACAAATAGTGATGTT  
 GGTGAGAAAAATAAGCTCCTGGAACATATTATAGACTGTGGAGATATAGCTCGGAGCTT  
 GCTTTTGGGTCTACAGTTCAGAAAAACAGAGTGCCTGTGTAAATATAGAAATGGCATCGC  
 TTCAGATTGGACAGATCAGCTACTTCTTGCTACAGGTTGAACATGGGCGTATCAAA  
 ATATGGGATGTATATACAGGAAAACTCCTCCTTAACTTGGTAGATCATACTGAAGTGGTC  
 20 AGAGATTAACTTTTGTCTCCAGATGGAAGCTTGATCCTGTGTGACCTTCAAGAGACAAA  
 ACTCTCAGAGTATGGGACCTGAAAGATGATGAAACATGATGAAAGTATTGAGGGGGCAT  
 CAGAAATTGGGTGTACAGCTGTGCATTCTCTCCTGACTCTTCTATGCTGTGTTCAGTCGGA  
 GCCAGTAAAGCAGTTTTCCTTTGGAATATGGATAAATACACCATGATACGGAACATAGAA  
 GGACATCACCATGATGTGGTAGCTGTGACTTTTCTCCTGATGGAGCATTACTGGCTACT  
 25 GCATCTTATGATACTCGAGTATATATCTGGGATCCACATAATGGAGACATTCTGATGGAA  
 TTTGGGCACTGTTTCCCCCACTACTCCAATATTGCTGGAGGAGCAAATGACCGGTGG  
 GTACGATCTGTATCTTTTAGCCATGATGGACTGCAATGTCAGCCTTGCTGATGATAAA  
 GGTCTTTGCTGTGCCTTCTCTACTGATGGCAGTGTTTAGCTGCTGGGACACATGACGGA  
 30 AGTGTGTATTTTGGGCCACTCCACGGCAGGTCCCTAGCCTGCAACATTATGTCCGATG  
 TCAATCCGAAGAGTATGCCCAACCAAGAAAGTTCAGGAGCTGCCGATTCTCTCAAGCTT  
 TTGGAGTTTCTCTCGTATCGTATTTAGAAAGATTCTGCCTTCCCTAGTAGAGGACTGAC  
 AGAATACACTTAACACAAACCTCAAGCTTTACTGACTCAATTATCTGTTTTTAAAGACG  
 TAGAAGATTATTTAATTTGATATGTTCTTGACTGCAATTTGATCAGTTGAGCTTTTAA  
 35 AATATTATTATAGACAAATAGAAGTATTTCTGAACATATCAAAATATAAATTTTAAAG  
 ATCTAACTGTGAAAACATACATACCTGTACATATTTAGATATAAGCTGCTATATGTTGAA  
 TGGACCTTTTGTCTTTCTGTATTTTAGTTCTGACATGATATATTGCTTCAGTAGAGCTG  
 ACAATATGTATCTTTGCTGTAAGTGCAAGGAAATTTAAATTTCTGGGCACTGAGTAG  
 40 ATGTTAAATAGTCACTTACGAAAGTGAATGGGTGAGGCGGGCAATCACTGAGGTCA  
 GCAGTTTGAGACTAGCCTGGCTAATTTTGTAGTTTGGTATGAGACAGGGTTTCACTGTG  
 TTGCCAGGCTGGTCCAGCTCCTGGCCTCAAGTGATCCACCACTCAGCCTCCAAAG  
 TGCTGGGATTACAGCATAAAGCACCACCTCCAGTCCACCAAAATGCTTCTGAAAGAGCT  
 GTCATAGCTTATATCTCTCCAAGAATACAATTTTCTGCATCCTCATCAGTATTAAATGC

TTTTATTTTATCCTAATTGCTAGCCCAAC

## SEQ ID NO:4

5 MASFPFRVNEKEIVLRRTIGELLAPAAPFDKKCGRENWTVAFAPDGSYFAWSQGHRTVKL  
VPWSQCLQNFLHGTQNVNTSSSLRLPRQNSDGGQKNKPREHIIDCGDIVWSLAFGSSVP  
EKQSRCVNIWHRFRFGQDQLLATGLNNGRIKIWDVYTGKLLNLVDHTEVVRDLTFAP  
DGSILVVSASRDKTLRVWDLKDDGNMVKLRGHQNWVYSCAFSPDSSMLCSVGASKAVFL  
WNMDKYTMIRKLEGGHHDVVACDFS PDGALLATASYDTRVYIWDPHNGDILMEFGHLFFP  
10 PTFI FAGGANDRWVRSVSF SHDGLHVASLADDMVRFWRIDEDYFVQVAPLSNGLCCAFS  
TDGSVLAAGTHDGSVYFWATPRQVPSLQHLCRMSIRRVMPQTQEVQELFIPSKLLEFLSYR  
I

## Claims

1. An isolated polypeptide comprising an amino acid sequence which has at least 95% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of of SEQ ID NO:2.
- 5 2. An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 98% identity.
3. The polypeptide as claimed in claim 1 comprising the amino acid sequence of SEQ ID NO:2.
- 10 4. The isolated polypeptide of SEQ ID NO:2.
5. An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 95% identity to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2; or a nucleotide sequence complementary to said isolated polynucleotide.
- 15 6. An isolated polynucleotide comprising a nucleotide sequence that has at least 95% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2, over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide.
- 20 7. An isolated polynucleotide which comprises a nucleotide sequence which has at least 95% identity to that of SEQ ID NO:1 over the entire length of SEQ ID NO:1; or a nucleotide sequence complementary to said isolated polynucleotide.
- 25 8. The isolated polynucleotide as claimed in any one of claims 5 to 7 in which the identity is at least 98%.
9. An isolated polynucleotide selected from:
  - (a) a polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2;
  - 30 (b) the polynucleotide of SEQ ID NO:1; and
  - (c) a polynucleotide obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof; or a nucleotide sequence complementary to said isolated polynucleotide

10. An expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression system is present in a compatible host cell.
11. A host cell comprising the expression system of claim 10 or a membrane thereof expressing the polypeptide of claim 1.
12. A process for producing a polypeptide of claim 1 comprising culturing a host cell of claim 11 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.
13. An antibody immunospecific for the polypeptide of claim 1.
14. A method for screening to identify compounds which stimulate or which inhibit the function of the polypeptide of claim 1 which comprises a method selected from the group consisting of:
- (a) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;
- (b) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor;
- (c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes bearing the polypeptide;
- (d) mixing a candidate compound with a solution containing a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a standard; or
- (e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide and said polypeptide in cells, using for instance, an ELISA assay.
15. An agonist or antagonist to the polypeptide of claims 1 to 4.
16. A compound which is:
- (a) an agonist or antagonist to the polypeptide of claims 1 to 4;
- (b) isolated polynucleotide of claims 5 to 9; or

- (c) a nucleic acid molecule that modulates the expression of the nucleotide sequence encoding the polypeptide of claim 1;  
for use in therapy.
- 5 17. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of the polypeptide of claim 1 in a subject comprising:
- (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said polypeptide in the genome of said subject; and/or
- (b) analyzing for the presence or amount of said polypeptide expression in a sample derived from
- 10 said subject.
18. An isolated polynucleotide selected from the group consisting of
- (a) an isolated polynucleotide comprising a nucleotide sequence which has at least 95% identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3;
- 15 (b) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:3;
- (c) the polynucleotide of SEQ ID NO:3; or
- (d) an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide which has at least 95% identity to the amino acid sequence of SEQ ID NO:4, over the entire length of SEQ ID
- 20 NO:4.
19. A polypeptide selected from the group consisting of
- (a) a polypeptide which comprises an amino acid sequence which has at least 95% identity to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4;
- (b) a polypeptide in which the amino acid sequence has at least 95% identity to the amino acid
- 25 sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4;
- (c) a polypeptide which comprises the amino acid of SEQ ID NO:4;
- (d) a polypeptide which is the polypeptide of SEQ ID NO:4; or
- (e) a polypeptide which is encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

## SEQUENCE LISTING

|    |  |      |
|----|--|------|
| 5  | <110> SmithKline Beecham plc                                       |      |
|    | <120> Novel Compounds  |      |
| 10 | <130> GP30086  |      |
|    | <150> 4  |      |
|    | <170> FastSEQ for Windows Version 3.0                              |      |
| 15 | <210> 1  |      |
|    | <211> 2068   |      |
|    | <212> DNA  |      |
|    | <213> Homo sapiens   |      |
| 20 | <400> 1  |      |
|    | ttgcggccgc ccccgcccg ctcctctgtc cctgggccgc ggaggaccca acttggcgtc   | 60   |
|    | acgcccccca gcggtcgcca ctctctcttc tgttgttggg tccgcacgt attccccgaa   | 120  |
|    | tcagacgggtg ccccatagat ggcacgcttt ccccgagggt tcaacgagaa agagatcgtg | 180  |
|    | agatcacgta ctataggtga acttttagct cctgcagctc cttttgacaa gaaatgtggt  | 240  |
| 25 | cgtgaaaatt ggactgttgc ttttgcctca gatggttcat actttgctg gtcacaaagg   | 300  |
|    | catgcacag taaagcttgc tccgtggctc cagtgccctc agaactttct cttgcattgc   | 360  |
|    | accaagaatg ttaccaattc aagcagttta agattgccaa gacaaaatag tgatgggtgt  | 420  |
|    | cagaaaaata agcctcgtga acatattata gactgtggag atatatgtctg gagtcttctc | 480  |
|    | ttttggtcat cagttccaga aaaacagagt cgctgtgtaa atatagaatg gcatcgcttc  | 540  |
| 30 | agatttggac aagatcagct acttcttgc acagggttga acaatgggcg tatcaaaata   | 600  |
|    | tgggatgtat atacaggaaa actcctcctt aacttggtag atcatactga agtggtcaga  | 660  |
|    | gatttaactt ttgctccaga tggaaagctg atcctgggtg cagcttcaag agacaaaact  | 720  |
|    | ctcagagat gggacctgaa agatgatgga aacatgatga aagtattgag gggcctcag    | 780  |
|    | aattgggtgt acagctgtgc attctctctc gactcttcta tgctgtgttc agtcggagcc  | 840  |
| 35 | agtaaagcag ttttcccttg gaatatggat aaatacacca tgatacggaa actagaagga  | 900  |
|    | catcaccatg atgtggtagc ttgtgacttt tctctgatg gagcattact ggctacttgc   | 960  |
|    | tcttatgata ctcgagtata tatctgggat ccacataatg gagacattct gatggaattt  | 1020 |
|    | gggcacctgt tccccccacc tactccaata ttgtctggag gagcaaatga cccgtgggta  | 1080 |
|    | cgatctgtat cttttagcca tgatggactg catgttgcaa gccttgctga tgataaaatg  | 1140 |
| 40 | gtgaggtctt ggaagaattga tgaggattat ccagtccaag ttgcaccttt gagcaatggt | 1200 |
|    | ctttgctgtg cctctctac tgatggcagt gttttagctg ctggtagggt cgggatttca   | 1260 |
|    | ccatgtctgc ctggctggtc tcaaaactct gacctgacc tcaagtgtac tccccgcctc   | 1320 |

|    |   |      |
|----|---|------|
|    | aacttcccaa agtgcgtggga ttacaggcga cacatgacgg aagtgtgtat ttttggggcca | 1380 |
|    | ctccacggca ggtccctagc ctgcaacatt tatgtcgcat gtcaatccga agagtgtatgc  | 1440 |
|    | ccaccaaga agttcaggag ctgccgattc ctccaagct ttggagttt ctctcgtate      | 1500 |
|    | gtatttagaa gattctgcct tccctagtag tagggactga cagaatacac ttaacacaaa   | 1560 |
| 5  | ctccaagctt tactgacttc aattatctgt ttttaaagc gtagaagatt tatttaattt    | 1620 |
|    | gatatgttct tgtactgcat ttgtatcagt tgagctttta aaatattatt tatagacaat   | 1680 |
|    | agaagtattt ctgaacatat caaatataaa tttttttaa gatctaaactg tgaanaacata  | 1740 |
|    | catacctgta catatttaga tataagctgc tatatgttga atggaccctt ttgcttttct   | 1800 |
|    | gatttttagt tctgacatgt atatattgct tcagttaggc cacaatatgt atctttgtcg   | 1860 |
| 10 | taaagtcaaa ggaaatttta aattctggga cactgagtta gatggtaaat actgacttac   | 1920 |
|    | gaaagttaga ttgggtgagg cgggcaaatc acctgaggtc agcagtttga gactagctcg   | 1980 |
|    | gcaaacatga tgaacccttg tctctaactaa aaatcctctg gccgaattct tggcctcgag  | 2040 |
|    | ggcacaattc cctatatgta gtcgtatt                                      | 2068 |
| 15 | <210> 2   |      |
|    | <211> 389   |      |
|    | <212> PRT   |      |
|    | <213> Homo sapiens  |      |
| 20 | <400> 2   |      |
|    | Met Ala Ser Phe Pro Pro Arg Val Asn Glu Lys Glu Ile Val Arg Ser     |      |
|    | 1 5 10 15   |      |
|    | Arg Thr Ile Gly Glu Leu Leu Ala Pro Ala Ala Pro Phe Asp Lys Lys     |      |
|    | 20 25 30  |      |
| 25 | Cys Gly Arg Glu Asn Trp Thr Val Ala Phe Ala Pro Asp Gly Ser Tyr     |      |
|    | 35 40 45  |      |
|    | Phe Ala Trp Ser Gln Gly His Arg Thr Val Lys Leu Val Pro Trp Ser     |      |
|    | 50 55 60  |      |
|    | Gln Cys Leu Gln Asn Phe Leu Leu His Gly Thr Lys Asn Val Thr Asn     |      |
| 30 | 65 70 75 80   |      |
|    | Ser Ser Ser Leu Arg Leu Pro Arg Gln Asn Ser Asp Gly Gly Gln Lys     |      |
|    | 85 90 95  |      |
|    | Asn Lys Pro Arg Glu His Ile Ile Asp Cys Gly Asp Ile Val Trp Ser     |      |
|    | 100 105 110   |      |
| 35 | Leu Ala Phe Trp Ser Ser Val Pro Glu Lys Gln Ser Arg Cys Val Asn     |      |
|    | 115 120 125   |      |
|    | Ile Glu Trp His Arg Phe Arg Phe Gly Gln Asp Gln Leu Leu Leu Ala     |      |
|    | 130 135 140   |      |
|    | Thr Gly Leu Asn Asn Gly Arg Ile Lys Ile Trp Asp Val Tyr Thr Gly     |      |
| 40 | 145 150 155 160   |      |
|    | Lys Leu Leu Leu Asn Leu Val Asp His Thr Glu Val Val Arg Asp Leu     |      |
|    | 165 170 175   |      |

|    |  |     |
|----|--|-----|
|    | Thr Phe Ala Pro Asp Gly Ser Leu Ile Leu Val Ser Ala Ser Arg Asp      |     |
|    | 180 185 190  |     |
|    | Lys Thr Leu Arg Val Trp Asp Leu Lys Asp Gly Asn Met Met Lys          |     |
|    | 195 200 205  |     |
| 5  | Val Leu Arg Gly His Gln Asn Trp Val Tyr Ser Cys Ala Phe Ser Pro      |     |
|    | 210 215 220  |     |
|    | Asp Ser Ser Met Leu Cys Ser Val Gly Ala Ser Lys Ala Val Phe Leu      |     |
|    | 225 230 235 240  |     |
|    | Trp Asn Met Asp Lys Tyr Thr Met Ile Arg Lys Leu Glu Gly His His      |     |
| 10 | 245 250 255  |     |
|    | His Asp Val Val Ala Cys Asp Phe Ser Pro Asp Gly Ala Leu Leu Ala      |     |
|    | 260 265 270  |     |
|    | Thr Ala Ser Tyr Asp Thr Arg Val Tyr Ile Trp Asp Pro His Asn Gly      |     |
|    | 275 280 285  |     |
| 15 | Asp Ile Leu Met Glu Phe Gly His Leu Phe Pro Pro Pro Thr Pro Ile      |     |
|    | 290 295 300  |     |
|    | Phe Ala Gly Gly Ala Asn Asp Arg Trp Val Arg Ser Val Ser Phe Ser      |     |
|    | 305 310 315 320  |     |
|    | His Asp Gly Leu His Val Ala Ser Leu Ala Asp Asp Lys Met Val Arg      |     |
| 20 | 325 330 335  |     |
|    | Phe Trp Arg Ile Asp Glu Asp Tyr Pro Val Gln Val Ala Pro Leu Ser      |     |
|    | 340 345 350  |     |
|    | Asn Gly Leu Cys Cys Ala Phe Ser Thr Asp Gly Ser Val Leu Ala Ala      |     |
|    | 355 360 365  |     |
| 25 | Gly Arg Val Gly Ile Ser Pro Cys Ser Pro Gly Trp Ser Gln Thr Pro      |     |
|    | 370 375 380  |     |
|    | Asp Pro Asp Leu Lys  |     |
|    | 385  |     |
| 30 | <210> 3  |     |
|    | <211> 2250   |     |
|    | <212> DNA  |     |
|    | <213> Homo sapiens   |     |
| 35 | <400> 3  |     |
|    | cggcgccttta ggggaaactgt ctctctccgc agcgcgagcgc tgggtacagg gtctattgtc | 60  |
|    | tgtgggttac tccgtacttt ggtctgagcgc ctccgggagc ttccccgagg cagttagcag   | 120 |
|    | aagcgcgagc ggcgcgcccc gccgtctccc tctgtccctg ggcccgaggag acaaaacttg   | 180 |
|    | cgctacgcgcc tcagcggctcg ccaactctctt ctctgtttgt gggtccgcac cgtattcccc | 240 |
| 40 | gaatcagacg gtgccccata gatggccagc ttccccccga ggggtcaacga gaaagagatc   | 300 |
|    | gtgagattac gtactatagg tgaactttta gctcctgcag ctccctttga caagaaatgt    | 360 |
|    | ggctcgtgaaa attggactgt tgccttttgt ccagatgggt cataccttgc ttggtcaaca   | 420 |



|    |   |      |
|----|---|------|
|    | ggacatcgca cagtaasgct tgttcctggt tccagatgcc ttcagaactt tctcttgcat   | 480  |
|    | ggccaacaaga atgttaccaa ttcaagcagt ttaagatgac caagacaaaa tagtgatggt  | 540  |
|    | ggtcagaaaa ataaagcctcg tgaacatatt atagactgtg gagatatagt ctggagctctt | 600  |
|    | gcttttgggt catcagttcc agaaaaacag agtcgctgtg taaatataga atggcatcgc   | 660  |
| 5  | ttcagatttg gacaagatca gctacttctt gctacagggt tgaacaatgg gcgtatcaca   | 720  |
|    | atctgggagtg tatatacagg aaaactcttc cttacttgg tagatcatac tgaagtggtc   | 780  |
|    | agagatttaa cttttgctcc agatggaagc ttgatcctgg tgcagcttc aagagacaaa    | 840  |
|    | actccagagc tatgggacct gaaagatgat ggaanacatga tgaagtatt gagggggcat   | 900  |
|    | cagaattggg tgtacagctg tgcattctct cctgactctt ctatgctgtg ttcagtcgga   | 960  |
| 10 | gccagtaaac cagttttcct ttggaatatg gataaatata ccatgatagc gaaactagaa   | 1020 |
|    | ggacatcacc atgatgtggt agcttgtgac ttttctctg atggagcatt actggctact    | 1080 |
|    | gcattcttat atactcgagt atatatctgg gatccacata atggagacat tctgatggaa   | 1140 |
|    | tttgggcacc tgtttccccc acctactcca atatttctg gaggagcaaa tgaccgtgg     | 1200 |
|    | gtacgatctg tatcttttag ccatgatgga ctgcatgttg caagccttgc tgatgataaa   | 1260 |
| 15 | atggtgagtg tctggagaat tgatgaggat tatccagtc aagttgcacc tttgagcaat    | 1320 |
|    | ggtctttgtg gtgccttctc tactgatggc agtgttttag ctgctgggac acatgacgga   | 1380 |
|    | agtgtgtatt tttgggccac tccacggcag gtccctgacc tgcaacattt atgtcgcatg   | 1440 |
|    | tcaatcgaag gagtgatgcc caccacaaga gttcaggagc tgccgatcc ttccaagett    | 1500 |
|    | ttggagtttc tctcgatcg tatttagaag attctgcctt ccctagtagt agggactgac    | 1560 |
| 20 | agaatacact taacacaaac ctcaagcttt actgacttca attatctggt tttaaagacg   | 1620 |
|    | tagaagattt atttaatttg atagtctctt gtaactgcatt ttgatcagtt gagcttttaa  | 1680 |
|    | aatattattt atagacaata gaagtatttc tgaacatata aatatataat tttttaaag    | 1740 |
|    | atcttaactgt gaaaacatac atacctgtac atatttagat ataagctgct atatgttgaa  | 1800 |
|    | tggacccttt tgcttttctg atttttagtt ctgacatgta tatattgctt cagtagagcc   | 1860 |
| 25 | acaatatgta tctttctgtc aaagtgcagg gaaattttaa attctgggac actgagttag   | 1920 |
|    | atggttaata ctgacttacc aaagttgaat tgggtgaggc gggcaaatca cctgaggtca   | 1980 |
|    | gcagtttgag actagcctgg ctaatttttg tagtttggg agagacaggg ttctactgtg    | 2040 |
|    | ttgccaggc tgggtccagc tcttggcctc aagtgatcca cccacctcag cctcccaag     | 2100 |
|    | tgctgggatt acagcataag ccaccactcc cagtccacca aattgccttc tgaagagact   | 2160 |
| 30 | gtcatagctt atattctctc caagaataca attttcctgc atcctcatca gtttaatgc    | 2220 |
|    | ttttatttta tctcaatttg ctageccane                                    | 2250 |

&lt;210&gt; 4

&lt;211&gt; 421

35 &lt;212&gt; FRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

Met Ala Ser Phe Pro Pro Arg Val Asn Glu Lys Glu Ile Val Arg Leu  
 1 5 10 15  
 Arg Thr Ile Gly Glu Leu Leu Ala Pro Phe Asp Lys Lys  
 20 25 30

Cys Gly Arg Glu Asn Trp Thr Val Ala Phe Ala Pro Asp Gly Ser Tyr  
 35 40 45  
 Phe Ala Trp Ser Gln Gly His Arg Thr Val Lys Leu Val Pro Trp Ser  
 50 55 60  
 5 Gln Cys Leu Gln Asn Phe Leu Leu His Gly Thr Lys Asn Val Thr Asn  
 65 70 75 80  
 Ser Ser Ser Leu Arg Leu Pro Arg Gln Asn Ser Asp Gly Gly Gln Lys  
 85 90 95  
 10 Asn Lys Pro Arg Glu His Ile Ile Asp Cys Gly Asp Ile Val Trp Ser  
 100 105 110  
 Leu Ala Phe Gly Ser Ser Val Pro Glu Lys Gln Ser Arg Cys Val Asn  
 115 120 125  
 Ile Glu Trp His Arg Phe Arg Phe Gly Gln Asp Gln Leu Leu Ala  
 130 135 140  
 15 Thr Gly Leu Asn Asn Gly Arg Ile Lys Ile Trp Asp Val Tyr Thr Gly  
 145 150 155 160  
 Lys Leu Leu Leu Asn Leu Val Asp His Thr Glu Val Val Arg Asp Leu  
 165 170 175  
 Thr Phe Ala Pro Asp Gly Ser Leu Ile Leu Val Ser Ala Ser Arg Asp  
 180 185 190  
 20 Lys Thr Leu Arg Val Trp Asp Leu Lys Asp Asp Gly Asn Met Met Lys  
 195 200 205  
 Val Leu Arg Gly His Gln Asn Trp Val Tyr Ser Cys Ala Phe Ser Pro  
 210 215 220  
 25 Asp Ser Ser Met Leu Cys Ser Val Gly Ala Ser Lys Ala Val Phe Leu  
 225 230 235 240  
 Trp Asn Met Asp Lys Tyr Thr Met Ile Arg Lys Leu Glu Gly His His  
 245 250 255  
 His Asp Val Val Ala Cys Asp Phe Ser Pro Asp Gly Ala Leu Leu Ala  
 260 265 270  
 30 Thr Ala Ser Tyr Asp Thr Arg Val Tyr Ile Trp Asp Pro His Asn Gly  
 275 280 285  
 Asp Ile Leu Met Glu Phe Gly His Leu Phe Pro Pro Pro Thr Pro Ile  
 290 295 300  
 35 Phe Ala Gly Gly Ala Asn Asp Arg Trp Val Arg Ser Val Ser Phe Ser  
 305 310 315 320  
 His Asp Gly Leu His Val Ala Ser Leu Ala Asp Asp Lys Met Val Arg  
 325 330 335  
 Phe Trp Arg Ile Asp Glu Asp Tyr Pro Val Gln Val Ala Pro Leu Ser  
 340 345 350  
 40 Asn Gly Leu Cys Cys Ala Phe Ser Thr Asp Gly Ser Val Leu Ala Ala  
 355 360 365

Gly Thr His Asp Gly Ser Val Tyr Phe Trp Ala Thr Pro Arg Gln Val  
370 375 380  
Pro Ser Leu Gln His Leu Cys Arg Met Ser Ile Arg Arg Val Met Pro  
385 390 395 400  
5 Thr Gln Glu Val Gln Glu Leu Pro Ile Pro Ser Lys Leu Leu Glu Phe  
405 410 415  
Leu Ser Tyr Arg Ile  
420

# INTERNATIONAL SEARCH REPORT

Intern. Appl. No.

PCT/EP 98/07886

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/47 C12N15/63 C07K16/18 G01N33/68  
C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | WO 98 20023 A (THE WALTER AND ELIZA HALL<br>INSTITUTE OF MEDICAL RESEARCH)<br>14 May 1998 (1998-05-14)<br>page 4, line 21 - page 16, line 7; table<br>1<br>page 33, line 3 - page 45, line 2<br>page 55, line 13 - page 61, line 18;<br>examples 17,20,22,25; tables 4.1.,4.2<br>see sequence SEQ ID NO:13, 14<br>---<br>-/- | 1-14,16,<br>17        |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document relating to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

14 April 1999

Date of mailing of the international search report

26.07.99

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

MONTERO LOPEZ B.

# INTERNATIONAL SEARCH REPORT

Inten. Appl. No.

PCT/EP 98/07806

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.              |
|------------|---|------------------------------------|
| X          | <p>DOUGLAS J. HILTON ET AL.: "Twenty proteins containing a C-terminal SOCS box form five structural classes"<br/>           PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA.,<br/>           vol. 95, no. 1,<br/>           6 January 1998 (1998-01-06), pages 114-119, XP002085497<br/>           WASHINGTON US<br/>           cited in the application<br/>           the whole document -----</p> | <p>1-14, 16,<br/>           17</p> |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 98/07806

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 15, 16 partially  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
Claims 1-17.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-17

Polypeptide of sequence SEQ ID NO:2, its analogs and derivatives; polynucleotide of sequence SEQ ID NO:1, its analogs and derivatives; expression system and host cell comprising the same and its use for the production of the polypeptide; antibody immunospecific for the polypeptide; method for screening compounds which stimulate or inhibit the function of the polypeptide; agonist and antagonists to the polypeptide; method for diagnosing a disease related to the expression or activity of the polypeptide.

2. Claims: 18, 19

Polypeptide of sequence SEQ ID NO:4, analogs and derivatives thereof; polynucleotide of sequence SEQ ID NO:3, analogs and derivatives thereof.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 15, 16 partially

Claims referring to agonists and antagonists have not been searched due to the lack of adequate technical description therefore in the application

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



## INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No

PCT/EP 98/07806

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)   | Publication<br>date      |
|---|---------------------|------------------------------|--------------------------|
| WO 9820023 A                              | 14-05-1998          | AU 4694397 A<br>GB 2331753 A | 29-05-1998<br>02-06-1999 |
| -----                                     |                     |                              |                          |